Ortho Regenerative Technologies Inc. Announces CFO Change

KIRKLAND, Quebec, Aug. 31, 2018 (GLOBE NEWSWIRE) — Ortho Regenerative Technologies Inc. (CSE: ORTH) (“Ortho RTi” or the “Corporation”) announces that Benedek (Ben) Simo has been appointed Interim Chief Financial Officer, effective immediately. Mr. Simo succeeds Jo-Anne Piché who is leaving the Corporation to pursue other professional projects.

“Jo-Anne has made many contributions to the Corporation and we wish her all the best in her future endeavors,” said Ortho RTi’s Executive Chairman and CEO, Dr. Brent Norton.  “At the same time, we are excited to have attracted an executive of Ben’s caliber to this position. With his depth of financial experience and proven track record of driving value in financial management, we believe that Ben is ideally suited to serve in this role.”

Mr. Simo has over 15 years of experience in financial management with both private and public companies across a variety of sectors.  Most recently, he was Manager, Financial Reporting at Resolute Forest Products, a NYSE- and TSX-listed global leader in the forest products industry with approximately US$3.5 billion in annual revenues.  Prior to that, he served as Financial Controller at Synchronica Inc, an AIM- and TSX-Venture Exchange-listed developer of next-generation mobile messaging solutions that was acquired by Myriad Group AG in 2012.  Previously, Mr. Simo held financial management positions at TouchTunes Interactive Networks, McCain Foods Limited and Ipex Group.  Mr. Simo earned a bachelor’s degree in economics from McGill University, his MBA from Saint Mary’s University, and has obtained a CPA auditor, CA designation.  

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Caution regarding forward-looking statements

This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further Information, please contact:

Stephen Kilmer
Investor & Media Relations
647.872.4849
kilmer@orthorti.com

Paragon 28® adds novel syndesmotic repair solution to its robust ankle fracture portfolio – Gorilla® Breakaway Screw System

ENGLEWOOD, Colo.Aug. 31, 2018 /PRNewswire/ — Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation that help to streamline procedures, allow surgeons flexibility in technique and approach, and facilitate reproducible results benefitting both the surgeon and patient.

The Paragon 28® Gorilla® Breakaway Screw System was designed to offer surgeons an improved design over traditional screws when used for syndesmotic fixation.

There are inherent challenges in addressing syndesmotic repair including:

  • Providing stable fixation while the syndesmosis heals
  • Soft tissue irritation
  • Screw fracture and removal of fractured implants

The Gorilla® Breakaway Screw System was designed with these challenges in mind. A rigid construct allows the syndesmosis to heal while a low-profile head limits soft tissue irritation. While broken and loose screws have demonstrated improved patient outcomes as compared to intact syndesmotic screws1, the location of screw breakage can be unpredictable with some breakage causing osteolysis from adjacent bony erosion leading to pain and difficult removal.2

The Breakaway Screw System was designed so that if screw fracture occurs, the screw breaks cleanly in the clear space at the notch point. Multiple removal features allow the surgeon to remove the screw fragments medially or laterally, if necessary.

Two notch lengths (14 and 17 mm) were designed to address differences in patient anatomy and to accommodate screw use with or without a plate. The notch is designed to be placed in the clear space when used for syndesmosis repair.

If removal is desired, the tibial component of the Breakaway Screw may be removed medially or laterally utilizing dedicated removal instrumentation.

Paragon 28® is grateful for the significant contributions Dr. John Kwon, MD and Dr. Matthew Riedel, MD have made as the surgeon designers of this system.

About Paragon 28, Inc.

Paragon 28, Inc. was established in 2010 to address the unmet and under-served needs of the foot and ankle community. From the onset, Paragon 28 has made it our goal to re-invent the space of foot and ankle surgery. We believe that through research and innovation we can create new and improved solutions to the challenges faced by foot and ankle specialists.

1. Manjoo A, Sanders DW, Tieszer C, Macleod MD. Functional and radiographic results of patients with syndesmotic screw fixation: implications for screw removal.

J Orthop Trauma. 2010;24:2-6

2. Riedel MD, Briceno J, Miller C, Kwon J Technical tip: Removal of a broken tri-cortical syndesmotic screw using a “perfect circle” technique. Injury. 201 B Apr;49(4):877-880. doi: 10.1 016/j.injury.2018.02.022. Epub 2018 Mar 2.

Product Page:

www.paragon28.com

Contact:

Jim Edson

1-971-4007193

jedson@paragon28.com


SOURCE Paragon 28, Inc.

Photo: PRNewsfoto/Paragon 28, Inc

Related Links

http://www.paragon28.com

Captiva Spines’s TirboLOX-L™ Dual Layer Organic Lattice Structure 3D Printed Titanium Lumbar Cages Receive Clearance

Jupiter, FL, August 2018 – Captiva Spine is a medical device organization located in Jupiter, Florida, dedicated to delivering smart, elegant and intuitive spinal fusion solutions. Today, Captiva Spine is announcing it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its TirboLOX-L 3D Printed Titanium Lumbar Cages.

TirboLOX-L Titanium Lumbar Cages

TirboLOX-L Titanium Lumbar Cages are created using advanced 3D printing technologies to form titanium alloy interbody fusion devices with a dual layer organic lattice structure. This lattice structure features a micro-rough surface topography, interconnected dual porosity, and open architecture.  Titanium alloy implants with micro-rough surface topographies and dual porosity have been shown to promote direct bony ongrowth, ingrowth and vascularization. TirboLOX-L’s open architecture is designed to reduce radiographic presence for clear imaging.  TirboLOX-L’s high coefficient of friction creates immediate bidirectional fixation.

Dennis Ty, Director of R&D of Captiva Spine declared, “With the advanced capabilities of 3D Additive Manufacturing we were able to create a unique lattice structure similar to trabecular bone incorporating a micro-rough surface for clot retention and early osteogenic cell migration, including a dual layer of porosity with pore sizes specifically designed to promote bone ingrowth and vascularization.  Through substantial surgeon design input we are able to deliver TirboLOX-L’s unique dual layer organic lattice structure with numerous geometries and sizes that appeal to a wide range of surgeon preferences.”

Dale Mitchell, President and Founder of Captiva Spine said, “I am pleased our development team was able to incorporate our proprietary Pivotec® Pivoting TLIF Cage into TirboLOX.  Pivotec technology has been used in thousands of surgeries to address the challenges of controlling cage insertion and angle manipulation during surgery and is now available in a wide range of porous Titanium 3D printed, sterile packaged implants. This is especially important during minimally invasive (MIS) applications where time and safety is always of the essence.”

Captiva Spine’s TirboLOX-L Lumbar Cages are one of five new product launches that will be featured at Booth 1649 during the North American Spine Society (NASS) Annual Meeting held in Los Angles, September 26-28, 2018.

Inquiries from tenured distribution professionals looking to partner with a company to build a relationship for the long run are always welcome.

For sales, contact:
Chip Jones, Director of Sales and Marketing
chip.jones@captivaspine.com or 561-277-9480 ext. 725
or via their website www.captivaspine.com/contact-us.

About Captiva Spine, Inc.

As a privately owned medical device organization founded in 2007, Captiva Spine supports spine surgeons, tenured spine distributors, and healthcare facilities in providing patients with progressive spinal care and an obsessive focus on quality.  They strive to create and maintain sincere, honest, collaborative relationships. By valuing their relationships above all else, it fosters the mutual trust and openness needed for Captiva Spine to be a conduit of high quality, smart, elegant, and intuitive patient solutions. As a family of industry professionals, Captiva Spine takes pride in delivering these solutions responsibly and ethically while never losing sight of what they refer to as the Human Factor: Finding the joy in their daily lives and serving the needs of their customers with sincere, professional enthusiasm.

 

This Press Release can be found at PRWeb.com and is also featured on other media outlets.

EOS imaging Installs Its First Site in Mexico

September 04, 2018

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced the first installation of an EOS® system in Mexico, the largest Central American market, at Shriners Hospitals for Children – Mexico, located in Mexico City.

“Shriners Hospitals for Children – Mexico, noted for excellent pediatric specialty care, modern medical technology and exceptional personnel, is proud to bring the EOS technology to our facility,” said Dr. Mariano Gonzalez Lugo, Hospital Administrator. “The ability to obtain full-body, weight-bearing images of our patients will further enhance the orthopedic care we provide. In addition, the EOS system produces images with far less patient exposure to radiation than conventional X-rays. Our patients deserve safe, quality imaging and this is an important step in the right direction.”

Established in 1945, Shriners Hospital for Children – Mexico today has 80 beds and four operating rooms to treat patients up to 18 years of age for general pediatric orthopedics including upper- and lower-extremity surgeries, spine surgeries and bone lengthening and correction surgeries.

We applaud the Shriners Hospitals for Children for their commitment to safe imaging and are excited to see our footprint expand into Mexico,” commented Marie Meynadier, CEO of EOS imaging. “This is the first facility to adopt our system in Mexico City, serving more than 12 million inhabitants. It marks a significant step towards making our solutions available to Central American patients and healthcare providers.”

About EOS imaging

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteo-articular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Marie Meynadier, +33 (0)1 55 25 60 60
CEO
investors@eos-imaging.com
or
Press Relations (US)
The Ruth Group
Kirsten Thomas, 508-280-6592
kthomas@theruthgroup.com
or
Investor Relations (US)
The Ruth Group
Matt Picciano / Emma Poalillo, 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com

TransEnterix, Inc. Appoints Eric Smith as Chief Commercial Officer

September 04, 2018

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Eric Smith has been named Chief Commercial Officer, effective August 31, 2018.

In this newly created role, which will report directly to the Chief Executive Officer, Mr. Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence.

“We are very excited to have Eric join the TransEnterix team. He brings a wealth of experience commercializing innovative technologies on a global scale,” said Todd M. Pope, Chief Executive Officer of TransEnterix. “As we look to drive widespread adoption of Senhance, we believe that the addition of Eric’s expertise in developing and driving sales and marketing strategies will complement our existing team as we continue to grow and increase our presence in the United States and around the world.”

Mr. Smith brings over two decades of medical technology experience to TransEnterix, with over a decade of that focused on commercial leadership and marketing strategy. Most recently, he was a Vice President, Franchise Leader Acute Care at KCI Corporation, a developer and manufacturer of wound healing products. While at KCI, he was responsible for the development and commercialization of innovative wound-care technologies on a global scale. Prior to joining KCI, Mr. Smith served as Vice President of Global Strategic Marketing at Cordis Corporation, a developer and manufacturer of medical devices for the treatment of coronary and peripheral vascular diseases. He has also held senior positions at Boston Scientific, C.R. Bard and Ernst & Young. He received his Bachelor’s degree from the University of New Hampshire and his MBA from Babson College.

“I am extremely pleased to be joining TransEnterix during such an exciting time in the company’s history,” said Smith. “Senhance is a transformative technology with a large market opportunity, and I look forward to contributing to the company’s success and improving clinical outcomes and patient care through the use of digital laparoscopy.”

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The Company is focused on the commercialization of the Senhance™ Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical System and our current commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Mr. Smith’s expertise in developing and driving sales and marketing strategies will complement TransEnterix’s existing team as TransEnterix continues to group and increase its presence in the United States and around the world and whether Mr. Smith can contribute to TransEnterix’s success and improving clinical outcomes and patient care through the use of digital laparoscopy. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 8, 2018 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

For TransEnterix, Inc.
Investors:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media:
Joanna Rice, +1 951-751-1858
joanna@greymattermarketing.com

NuVasive To Feature Lateral Single-Position Surgery And Surgical Intelligence At SMISS Annual Forum

SAN DIEGOSept. 4, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ : NUVA ), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company will showcase industry-leading solutions for creating better clinical outcomes for spine procedures at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum being held September 6-8, 2018, in Las Vegas at Caesars Palace.

During SMISS 2018, NuVasive will feature its Lateral Single-Position Surgery procedure benefits, which may include reducing the number of times a patient has to be repositioned for greater operating room (OR) efficiency, along with the other benefits of minimally invasive spine surgery. Attendees will hear directly from leading surgeons of the procedure and learn what NuVasive is doing to incorporate advanced materials into its surgical implants. Attendees will also hear more about the Surgical IntelligenceTM ecosystem which incorporates the LessRay® technology to proactively combat radiation exposure in the OR. LessRay offers the surgeon and hospital system the opportunity to use significantly reduced radiation imaging in the OR, while providing image stitching for surgeons to quickly combine together fluoroscopic images of any spine segment.

In addition, the NuVasive industry lunch session, Leading. Expanding. Advancing. Insights to Lateral Procedural Solutions and Technology, by Adam Kanter, M.D., neurosurgeon at University of Pittsburgh Medical Center, will take place on Friday, September 7 from 12:50-1:10 p.m. PT in Roman Ballroom Exhibit Hall.

“As a leader in minimally invasive spine surgery, NuVasive views SMISS as a dedicated industry meeting with a shared mindset that provides a valuable forum where we can partner with surgeons to advance learnings of new technologies and procedures,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “Specifically, we will show safer, faster and smarter surgery through Surgical Intelligence, our leadership position in Lateral Single-Position Surgery and the benefits our comprehensive procedural solutions offer to surgeons, patients and hospital systems.”

Conference attendees can visit NuVasive Booth #309 to experience the latest innovative spine solutions and systems firsthand from the NuVasive team of experts.

About NuVasive

NuVasive, Inc. (NASDAQ : NUVA ) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Orthopaedic Surgeon Dr. Jeffrey Carlson Completes Milestone Case With SpineFrontier’s Invue Technology

SpineFrontier announced today that Dr. Jeffrey R. Carlson completed his 500th case using SpineFrontier’s Invue plate and screws, with no recorded screw backouts. The operation took place on Aug. 21 at Mary Immaculate Hospital in Newport News, Va. Dr. Carlson performed a one-level anterior cervical discectomy and fusion. Prior to undergoing surgery, the patient’s neck pain was constant along with left upper extremity pain and numbness in the right forearm. She failed conservative treatments including physical therapy, chiropractics, pain management and an epidural steroidal injection. Cervical X-rays revealed degenerative disc disease and kyphosis and her MRI showed spinal stenosis and a herniated disc at C5-6. This surgery was performed as an outpatient Less Exposure Surgery (LES) procedure and the patient was discharged just two hours post operatively.

The Invue screw’s connected tab feature provides enhanced feedback for secure final screw locking, a close design collaboration between Dr. Carlson and SpineFrontier.

“The Invue anterior plating system has a twofold screw locking mechanism. The first is a thread-through feature, where both the major and minor diameters of the screw are timed with the plate’s screw hole. The second is the connected ‘hurricane tabs’ (also referred to as locking arms) which snap and lock into place underneath the plate’s lip. The dual locking mechanism provides a robust plate-to-screw interface to prevent screw backout, while the connected tab feature provides the user with tactile, visual and audible confirmation of the lock,” said SpineFrontier Lead Product Manager Mike Bache.

Dr. Carlson’s case represents an evolution in the performance of cervical plating screws. Moreover, this surgical milestone proves an achievement for the innovative LES approach, which results in smaller incisions, minimizes tissue disruption, and reduces blood loss and surgery time. The LES approach provides a potentially speedier recovery.

Dr. Carlson noted, “We haven’t had a single Invue screw back out since we began utilizing the product. Prior to using SpineFrontier technology, we generally saw one to two patients annually with a backout issue, which became our expectation regarding results. With the Invue screw, we’ve fortunately reversed that presumption of patient return.”

Dr. Jeffrey Carlson serves as President and Managing Partner of the Orthopaedic & Spine Center in Newport News, Va. He is a board-certified, fellowship-trained spine specialist who focuses on the treatment of injuries and disorders of the spine. He is a thought leader and pioneer in the development and implementation of outpatient spinal surgery procedures and techniques, including Less Exposure Surgery, which is minimally invasive and less traumatic for the patient.

Dr. Carlson received his Bachelor of Science from the University of Maryland and promptly began medical school at George Washington University. Post-graduate training included his residency at Harvard University, and two fellowships.

About SpineFrontier Inc.
SpineFrontier’s mission is to advance the standard of spine surgery through innovative technology. SpineFrontier believes less is more: less time in treatment and recovery is more time in action for patients and surgeons. Headquartered in Malden, Ma., SpineFrontier is a KICVentures portfolio company and the leader in LES technologies and instruments.

FDA Grants Eden Spine 510(K) Clearance for Its Thoraco Lumbar Spine Locking Plate – SPHYNX™

The SPHYNX™ is the ideal complement to Eden Spine proprietary, expandable titanium vertebral body replacement implant with rotatable endplates, the GIZA™ which provides multiple angulation options by simple endplates rotation. The GIZA™ is intended to replace and fuse a collapsed, damaged, or unstable vertebral body due to a tumor or a fracture.

Made of titanium, the low profile SPHYNX™ is to be implanted via the antero-lateral approach for the treatment of thoraco-lumbar instabilities. Indications include spinal fractures, vertebral tumors, secondary instabilities of the thoracic and thoraco-lumbar spine, and any other indication requiring an anterior stabilization low profile.

“The SPHYNX™ is the latest innovation coming from our R&D department in Geneva, Switzerland,” says Ben Mokhtar, President of Eden Spine Europe, SA. “Our goal was to develop a technology that was simple to use, intuitive, and worked with the anatomy. To achieve that goal we have developed a cutting edge integrated locking system, minimized the thickness of the implant in an effort to respect the surrounding tissues, and maximized the range of precurved plates, to provide optimal adaptation to patient’s anatomy.”
The SPHYNX™ was granted CE Mark approval in 2016.
——-
About Eden Spine Europe SA: 
Eden Spine is a privately held, technology driven spinal organization based in Switzerland since 2005. The company distributes a range of innovative spinal technologies in the United States and abroad. Eden Spine patented portfolio is composed of a mix of fusion and non-fusion technologies.

For distribution opportunities, please contact us at
Customer.service(at)edenspine(dot)com or visit http://www.edenspine.com

K2M Group Holdings, Inc. Announces Definitive Agreement To Be Acquired by Stryker Corporation

LEESBURG, Va., Aug. 30, 2018 (GLOBE NEWSWIRE) — K2M Group Holdings, Inc. (Nasdaq:KTWO) (the “Company” or “K2M”), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance, today announced a definitive merger agreement with Stryker Corporation (“Stryker”, NYSE:SYK) pursuant to which Stryker has agreed to acquire all of the issued and outstanding shares of common stock of K2M in an all cash transaction for $27.50 per share, or a total equity value of approximately $1.4 billion. The purchase price represents a 27% premium over K2M’s average closing price during the 90 trading days ended August 29, 2018. Upon completion of the proposed transaction, K2M will become a wholly owned subsidiary of Stryker Corporation. Post-closing, K2M’s Chairman, Chief Executive Officer, and President Eric D. Major is expected to be appointed as the President of Stryker’s Spine division.

“Joining Stryker will be a very exciting next chapter for our global team and surgeon customers around the world,” said Chairman, Chief Executive Officer, and President of K2M, Eric D. Major. “Stryker’s established leadership in the orthopedic and neurosurgical market, combined with K2M’s culture of innovation and leadership in complex spine and minimally invasive solutions, represent a powerful opportunity for Stryker to strengthen its leadership in the $10 billion global spine market”.

“This acquisition underscores our commitment to the spinal market, which is the largest segment of Orthopaedics with significant unmet needs,” stated Kevin A. Lobo, Chairman and Chief Executive Officer, Stryker. “We believe K2M will significantly enhance our presence with surgeons, patients and employees in both the spine and related neurotechnology markets.”

The proposed transaction is expected to close late in the fourth quarter of 2018, subject to customary closing conditions, including approval by K2M’s stockholders and the receipt of certain regulatory approvals. The proposed transaction has been approved by the Board of Directors of both companies and is not subject to any financing condition.

In connection with this transaction, Piper Jaffray & Co. is acting as financial advisor and Simpson Thacher & Bartlett LLP is acting as legal advisor to K2M.

About K2M Group Holdings, Inc.

K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques and leadership in the 3D-printing of spinal devices, enables K2M to compete favorably in the global spine surgery market. For more information, visit www.K2M.com and connect with us on FacebookTwitterInstagramLinkedIn and YouTube.

About Stryker Corporation

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Forward-Looking Statements

The foregoing contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements.  These forward-looking statements include statements relating to the expected timing, completion and effects of the proposed merger, as well as other statements representing management’s beliefs about, future events, transactions, strategies, operations and financial results, including, without limitation, our expectations with respect to the costs and other anticipated financial impacts of the merger; future financial and operating results of K2M Group Holdings, Inc. (“K2M”); K2M’s plans, objectives, expectations and intentions with respect to future operations and services; required approvals to complete the merger by our stockholders and by governmental regulatory authorities, and the timing and conditions for such approvals; the stock price of K2M prior to the consummation of the transactions; and the satisfaction of the closing conditions to the proposed merger.  Such forward-looking statements often contain words such as “assume,” “will,” “anticipate,” “believe,” “predict,” “project,” “potential,” “contemplate,” “plan,” “forecast,” “estimate,” “expect,” “intend,” “is targeting,” “may,” “should,” “would,” “could,” “goal,” “seek,” “hope,” “aim,” “continue” and other similar words or expressions or the negative thereof or other variations thereon.  Forward-looking statements are made based upon management’s current expectations and beliefs and are not guarantees of future performance.  Such forward-looking statements involve numerous assumptions, risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any such statements.  Our actual business, financial condition or results of operations may differ materially from those suggested by forward-looking statements as a result of risks and uncertainties which include, among others, those risks and uncertainties described in any of our filings with the Securities and Exchange Commission (the “SEC”).  Certain other factors which may impact our business, financial condition or results of operations or which may cause actual results to differ from such forward-looking statements are discussed or included in our periodic reports filed with the SEC and are available on our website at www.k2m.com under “Investor Relations.” You are urged to carefully consider all such factors.  Although it is believed that the expectations reflected in such forward-looking statements are reasonable and are expressed in good faith, such expectations may not prove to be correct and persons reading this communication are therefore cautioned not to place undue reliance on these forward-looking statements which speak only to expectations as of the date of this communication.  We do not undertake or plan to update or revise forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections, or other circumstances occurring after the date of this communication, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized.  If we make any future public statements or disclosures which modify or impact any of the forward-looking statements contained in or accompanying this communication, such statements or disclosures will be deemed to modify or supersede such statements in this communication.

Additional Information and Where to Find It

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval.  This communication relates to a proposed acquisition of K2M by Stryker Corporation.  In connection with this proposed acquisition, K2M may file one or more proxy statements or other documents with the SEC.  This communication is not a substitute for any proxy statement or other document K2M may file with the SEC in connection with the proposed transaction.  INVESTORS AND SECURITY HOLDERS OF K2M ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.  Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of K2M.  Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by K2M through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by K2M will be available free of charge on K2M’s internet website at www.k2m.com or upon written request to: Secretary, K2M Group Holdings, Inc., 600 Hope Parkway, SE, Leesburg, Virginia 20175, or by telephone at (703) 777-3155.

Participants in Solicitation

K2M, its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction.  Information regarding the persons who may, under the rules of the SEC, be deemed participants in such solicitation in connection with the proposed merger will be set forth in the proxy statement if and when it is filed with the SEC.  Information about the directors and executive officers of K2M is set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 1, 2018, its proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on April 20, 2018, its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2018 and June 30, 2018, which were filed with the SEC on May 2, 2018 and August 2, 2018, respectively, and its Current Reports on Form 8-K or Form 8-K/A, which were filed with the SEC on January 8, 2018, January 9, 2018, February 28, 2018, March 29, 2018, May 1, 2018, June 11, 2018, June 14, 2018, June 18, 2018 and August 1, 2018.

These documents can be obtained free of charge from the sources indicated above.  Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.Mike Piccinino, CFA
443-213-0500
K2M@westwicke.com

Sports Medicine Market USD 9,655.6 Mn Revenue Expected by 2023 | Increasing Awareness on Sports Injury to Drive Bright Future

Pune, India, Aug. 29, 2018 (GLOBE NEWSWIRE) — Market Research Future® has recently published its Premium Report on Global Sports Medicine Market which reveals that the sports medicine market is projected to grow at a promising CAGR of 8.9% during the forecast period of 2017 to 2023. Sports medicine is a necessary part of the sports and athletics sector due to its use in ensuring sportspeople and athletes are in the right physical condition to perform. The global sports medicine market is expected to reach an estimated USD 9,655.6 Mn by the end of 2023.

Global and regional sporting & athletic events have become highly commonplace with thousands of individuals participating in some capacity or the other. Recreational sports are often part of most curriculums in schools where participation is highly encouraged. Injuries in the line of extensive physical activities are inevitable. The global population is at an all-time high, and as such, growing incidences of sports injuries have been recorded which has increased the demand for sports medicine. Moreover, in response to rising sports-related injuries, there has been a noticeable increase in the number of sports medicine associations, thus driving market growth. Increasing awareness with regards to sports medicine as a niche part of the healthcare sector and rapid technological advancements in the healthcare sector is expected to be some other important drivers of the market.

High costs associated with sports medicine and unfavorable reimbursement policies are expected to hinder market growth. Lack of skilled professionals in sports medicine for the treatment of pediatric sports injuries is expected to pose a challenge to market growth. However, with growing awareness, the market represents untapped opportunities which are likely to expand the market, particularly in pediatric sports medicine in the coming years.

Get Exclusive Sample Report of Sports Medicine Market Report Enabled with Top 10 Players Geographical Overview and Respective Tables and Figures at https://www.marketresearchfuture.com/sample_request/3503

Key Players Overview Mentioned

MRFR has analyzed the competitive landscape of the global sports medicine market to reveal the various strategies employed by leading market players. Spreading awareness, the establishment of new sports medicine centers, and investments in research & development are some of the market strategies prominent players employ. Market players of note that have been included in the report are Smith & Nephew, Stryker, Medtronic, Zimmer Biomet, CONMED Corporation, Arthrex Inc., GE Healthcare, DePuy Synthes, and others.

Latest Industry News

  • The U.S based BWHealth, a sports injury prevention and treatment organization has received investments of USD 600,000 toward the scaling of its newest line of injury prevention products.
  • Stryker has acquired MITA LLC, a startup set up with the intention to offer a post free hip distraction system. The novel system carries great potential in sports medicine market.

Market Segmentation

MRFR’s segmental analysis has been performed on the basis of product, application, procedure, end-user, and region. By product, the Sports Medicine Market is segmented to include joint reconstructive & repair products, accessories & consumables, support & recovery products and others. The joint reconstructive & repair products segment has been sub-segmented into ligament repair devices, implants, fracture, prosthetic devices, arthroscopy devices, and others. The support and recovery products segment has been further divided to include topical pain relief products, monitoring devices, thermal therapy devices, braces & support, monitoring devices, and others.

By application, the market is divided into spine treatment, hip treatment, knee treatment, shoulder treatment, and others.

By procedure, the market is categorized into tendon to bone, cartilage repair, and tendinosis. The tendinosis segment accounts for over half of the total market share. Tendinosis is chronic in nature and afflicts tendons which experience continuous stress over time which is highly common is sportspeople and athletes who carry the same sporting activities for years on end.

By end user, the market is segmented into ambulatory care, trauma centers, hospitals & emergency care and others.

Globally, the market has been segmented region-wise into North America, Europe, Asia Pacific and the Middle East & Africa.

High Number of Sports Medicine Centers Boost North America to Leading Position

North America, with its inclusion of the U.S, accounts for a market share of 39%, thus making it the most significant region in the global sports medicine market. Sports and athletics possess high importance in this region with sports like football and baseball being highly popular. Physical education and athletics are encouraged from a young age and children often participate in various sporting activities. As a result, there is an increasing number of sports medical centers being established in the region to treat the rising occurrences of sports injuries thus augmenting market growth.

Meanwhile, the Asia Pacific is growing at the highest CAGR of 9.2% during the assessment period. The regions healthcare sector is witnessing swift growth, and awareness regarding sports injury and the growing importance of physical education has provided the sports medicine market with opportunities for growth.

Get Discount on Sports Medicine Market Report at https://www.marketresearchfuture.com/check-discount/3503

Related Reports

North America Sports Medicine & Therapies Market-Forecast to 2023

North America Sports Medicine & Therapies Market Research Report, By Product (Helping Fractures Heal, Surgical Devices, Arthroscopy Devices, Orthopaedic Braces), By Area Of Application (Spine, Foot And Knee, Hip, Shoulder And Elbow, Other), By Procedure (Tendinosis, Tendon To Bone, Cartilage Repair), By End User (Hospitals & Emergency Care, Trauma Centres, Ambulatory Care)- Forecast To 2023

Global Precision Medicine Market Research Report – Forecast to 2022

Global Precision Medicine Market Information, By Ecosystem (pharma & biotech companies, diagnostic tool companies, healthcare IT/ big data companies, clinical laboratories), By Sub-markets (companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics, molecular diagnostics, others), By Therapeutics (cancer/oncology, cardiovascular disease, central nervous system, infectious diseases, others) – Forecast to 2022

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com